|
|
Randomized Study of Three Plant Phenolic Compounds Versus Sulindac (Part A) or Curcumin (Part B) in Prevention of Colon Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Sulindac and Plant Compounds in Preventing Colon Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Prevention
|
|
|
|
Temporarily closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
RUH-SSH-190-0600 RUH-SSH-190-0698, NCI-V98-1425, NCT00003365
|
|
|
Objectives - Determine the response of the colonic epithelium in normal volunteers at average or above average risk of colon cancer, when given short term treatment with plant phenolics such as curcumin, rutin, and quercetin.
- Compare the colonic mucosal response to the plant phenolics with their response to sulindac in order to evaluate whether they share common mechanisms for colon cancer chemoprevention.
- Determine the lowest optimal dose for each of the three plant phenolics that is effective in modulating biomarkers of colon epithelial cell turnover and, therefore, potentially inhibiting colon cancer development.
- Assess the response of the colonic epithelium to curcumin in volunteers at average risk of colon cancer development.
Entry Criteria Disease Characteristics:
- Individuals at average risk (Parts A and B) or above average risk (Part A
only) for development of colon cancer
- Average risk individuals defined as:
- No history of colon adenomas
- No strong family history of colon polyps or cancer
- Above average risk individuals defined as:
- History of one or more sporadic adenomatous polyps
at least 0.5 cm in size
(either tubular, tubulovillous, or villous
adenomas)
- Have had polypectomy or refused this procedure
- No significant family history of adenomatous polyps,
colon cancer, or
hereditary nonpolyposis colorectal cancer or other
hereditary colon cancer
syndrome
- Polyps should not have had a focus of adenocarcinoma
within them
- No history of gastrointestinal cancer outside of the large bowel
- No other gastrointestinal mucosal epithelial disease
(e.g., Barrett's
esophagus, chronic or recurrent peptic ulcer
disease, celiac sprue, or
other disorders of nutrient absorption)
- No significant asymptomatic lesions on flexible sigmoidoscopy, such as
inflammation, premalignancy or malignancy
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: Endocrine therapy: Radiotherapy: Surgery: Other: - No concurrent coumadin
- No chronic use of nonsteroidal antiinflammatory drugs (unless
they can be stopped for 3 months)
- No other putative colon cancer chemoprevention agents (unless
they can be stopped for 3 months)
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - No platelet or coagulation abnormalities
- No personal or family history of a bleeding disorder
- Hematopoietic concentration must not be due to significant
acute or chronic disorder
Hepatic: Renal: Cardiovascular: - No uncontrolled hypertension
- No chronic congestive heart failure
- No history of endocarditis
- No history of rheumatic fever
- No cardiac valve prostheses
- No mitral valve prolapse that requires antibiotic
prophylaxis
Other: - HIV negative
- No gout
- No pancreatitis
- No other chronic viral infection
- No significant acute or uncontrolled chronic medical
illness
- Generally non-smoking (no more than 4 cigarettes per week,
i.e., not daily smokers)
- Must abstain from smoking for at least 1 month prior to
enrolling in the study
- No alcohol consumption of greater than 2 glasses of wine or
beer per day
- Normal weight (90-120% of optimum body weight) and body
habitus
- No change in weight within 5-10% of body weight within the
past year
- No history of inflammatory bowel disease (either ulcerative
colitis or Crohn's disease )
- No hearing or equilibrium disorders
- No other prior malignancy except resected carcinoma in situ of
the cervix or nonmelanoma skin cancer
- No allergies to sulindac or tartrazine dyes or prior severe
adverse reactions to nonsteroidal antiinflammatory drugs (asthma,
gastrointestinal bleeding, or renal insufficiency)
- No potential allergy to curcumin, quercetin, or rutin
- No gastrointestinal bleeding
- Not institutionalized, mentally disabled, or
incarcerated
- No unusually high intake of stored micronutrients or high
doses of supplemental calcium or folate
- Not pregnant or nursing
Expected Enrollment There will be 130 patients (110 in Part A and 20 in Part B) accrued into this
study. Outline This is a randomized, controlled, two part, single institution study.
Patients in Part B are randomized by gender. All patients undergo flexible sigmoidoscopic exam. - Part A: Patients, in cohorts of 5-10, receive one of the following five
treatments in addition to the control diet: nothing (arm I), oral sulindac
twice a day (arm II), oral rutin at 1 of 3 doses twice a day (arms III, IV,
and V), oral quercetin at 1 of 3 doses twice a day (arms V, VI, and VII), or
at 1 of 3 doses oral curcumin twice a day (arms VIII, IX, and X). Patients
are first randomized to the highest doses of rutin, quercetin, and curcumin
and then lower doses may be given in order to determine the minimally
effective dose. Treatment is continued for 6-10 weeks.
- Part B: Patients are randomized to receive the control diet only (arm I)
or the control diet plus oral curcumin twice a day (arm II) for 6-10
weeks.
Patients are followed every 2 weeks.
Trial Contact Information
Trial Lead Organizations Rockefeller University Hospital | | | Steven Shiff, MD, Protocol chair | | | |
Registry Information | | Official Title | | The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells | | Trial Start Date | | 1996-08-01 | | Registered in ClinicalTrials.gov | | NCT00003365 | | Date Submitted to PDQ | | 1998-06-04 | | Information Last Verified | | 2008-04-09 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|